Kidifer 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 350.00

Medicine Details

Category	Details
Generic	Iron sucrose
Company	General pharmaceuticals ltd

Therapeutic class: Haematinic
Iron Sucrose Injection USP is a brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use
Contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5-11.1
Disassociates into Iron and Sucrose by the reticuloendothelial system after intravenous administration
Iron transfers from the blood to a pool in the liver and bone marrow
Ferritin binds and sequesters Iron in a nontoxic form
Iron binds to plasma transferrin, which carries Iron within the plasma and extracellular fluid
Transferrin receptor located in the cell, transferrin-receptor complex returned to the cell membrane
Intracellular Iron becomes haemoglobin in circulating red blood cells
Elimination half-life: 6 h, total clearance: 1.2 L/h, non-steady state apparent volume of distribution: 10.0 L, steady-state apparent volume of distribution: 7.9 L
Iron component distributes mainly in blood and to some extent in extravascular fluid, significant amount distributes in the liver, spleen, and bone marrow
Sucrose component is eliminated mainly through urinary excretion

Adults and Elderly: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on hemoglobin level
Children: Limited data, recommended not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on haemoglobin level

Intravenous injection: Administer undiluted by slow intravenous injection at the recommended rate
Infusion: Preferably administered by drip infusion in a dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max. 20 ml 0.9% w/v Sodium Chloride
Before administration of the therapeutic dose in a new patient, a test dose should be injected to monitor adverse reactions

Kidifer Injection should not be administered concomitantly with oral iron preparations
Oral Kidifer therapy should not be given until 5 days after the last injection

Patients with evidence of Iron overload
Patients with known hypersensitivity to Iron Sucrose or any of its inactive components
Patients with anaemia not caused by Iron deficiency
Patients with history of allergic disorders including asthma, eczema, anaphylaxis, liver disease, and infections

Caution should be exercised to withhold Kidifer administration in the presence of evidence of tissue Kidifer overload
Periodic monitoring of hematologic and haematinic parameters required for patients receiving Kidifer
Hypersensitivity reactions may occur in patients receiving Kidifer
Caution should be taken to administer Kidifer according to recommended guidelines to avoid hypotension
Safety and effectiveness in pediatric patients not established
Caution should be taken in geriatric patients

Safety and effectiveness in pediatric patients not established
No overall differences in safety observed between the elderly and younger subjects
Greater sensitivity of some older individuals cannot be ruled out

Dosages in excess of Kidifer needs may lead to accumulation of Kidifer in storage sites leading to hemosiderosis
Periodic monitoring of Kidifer parameters may assist in recognizing Kidifer accumulation
Particular caution should be exercised to avoid Kidifer overload
Symptoms associated with overdosage or rapid infusion include hypotension, headache, vomiting, nausea, dizziness, joint aches, and cardiovascular collapse